The Anticoagulation Report
Section 1: Introduction -- The Drug That Requires a Partnership
A 61-year-old man in Georgetown, Guyana has atrial fibrillation. He is on warfarin 5 mg daily. His INR has been checked three times in the past year, each time at a different facility, and the results were recorded in a paper card he sometimes carries. Last month he was prescribed metronidazole for a dental abscess. Nobody checked his INR two days later. He also drinks a large glass of soursop leaf tea every morning because his aunt told him it was good for the heart. He eats callaloo three or four times a week.
His INR is currently 6.1. He has bruising on both arms and blood in his urine.
Every element of this scenario is common in Caribbean anticoagulation management. The INR instability driven by dietary Vitamin K variability. The drug interaction with metronidazole through CYP2C9 inhibition (Report 12). The herbal interaction with soursop leaf through additive hypotensive and possible antiplatelet mechanisms (Report 3). The fragmented monitoring across facilities. The paper-based record that is rarely present when the clinician needs it.
Warfarin is the most interaction-prone drug in routine clinical use. It has a narrow therapeutic index, a dose-response relationship that varies substantially between individuals and within the same individual over time, and an interaction profile that spans diet, prescription drugs, herbal products, and acute illness. It is also, for most Caribbean patients with atrial fibrillation, mechanical heart valves, or venous thromboembolism, the only anticoagulant available.
This report provides a single comprehensive reference for anticoagulation management in Caribbean practice -- from INR targets and dose adjustment through dietary interactions, drug interactions, herbal interactions, and the emerging role of direct oral anticoagulants.
Section 2: Warfarin -- How It Works and Why It Is So Difficult
2.1 The mechanism
Warfarin inhibits Vitamin K epoxide reductase, the enzyme that recycles oxidised Vitamin K. Vitamin K is required for the activation of clotting factors II, VII, IX, and X, and of the anticoagulant proteins C and S. By blocking Vitamin K recycling, warfarin depletes active clotting factors and prolongs the prothrombin time, measured as the INR.
The INR response to warfarin is delayed -- clotting factor levels do not fall immediately; the effect accumulates over 3-5 days as existing activated factors are cleared. This delay means that dose changes take days to manifest, and that interactions (which alter warfarin metabolism or Vitamin K intake) take days to change the INR.
2.2 The CYP2C9 and VKORC1 pharmacogenomics
Warfarin is primarily metabolised by CYP2C9, and its pharmacodynamic target (Vitamin K epoxide reductase) is encoded by the VKORC1 gene. Polymorphisms in both genes -- which vary in frequency across ethnic populations -- substantially affect the dose required:
- CYP2C9 poor metabolisers require lower doses (slower drug clearance)
- VKORC1 variants affect sensitivity to warfarin's effect
- Caribbean populations of African descent have a higher frequency of CYP2C9*5, *6, and *11 variants, which are associated with reduced metabolism and lower warfarin dose requirements compared to European-derived population averages
This pharmacogenomic reality means that standard starting doses (5 mg/day) may be too high for many Caribbean patients. Initiation should start at 2-3 mg/day in older patients, smaller patients, or those with comorbidities, with close INR monitoring in the first two weeks.
Section 3: INR Targets and Indications
| Indication | Target INR range |
|---|---|
| Atrial fibrillation (stroke prevention) | 2.0 -- 3.0 |
| Deep vein thrombosis / pulmonary embolism (treatment) | 2.0 -- 3.0 |
| DVT/PE (extended secondary prevention) | 2.0 -- 3.0 |
| Mechanical bileaflet mitral valve | 2.5 -- 3.5 |
| Mechanical aortic valve (low risk) | 2.0 -- 3.0 |
| Mechanical aortic valve (high risk or older valve) | 2.5 -- 3.5 |
| Antiphospholipid syndrome with thrombosis | 2.0 -- 3.0 (or 2.5 -- 3.5 for recurrent) |
| Rheumatic mitral stenosis with AF | 2.0 -- 3.0 |
Caribbean practice note: The most common indication for warfarin in the Caribbean is atrial fibrillation. For most of these patients, the target INR is 2.0-3.0. A target of 2.5 (the midpoint of the range) is a useful practical anchor. An INR of 2.0-3.0 reduces stroke risk by approximately 64% vs no anticoagulation; below 2.0 the benefit falls substantially.
Section 4: The Caribbean Diet and Vitamin K
Dietary Vitamin K is the most common cause of INR instability in Caribbean patients on warfarin. Vitamin K is found in leafy green vegetables and some other foods. When intake increases, clotting factor production increases and the INR falls -- the warfarin effect is reduced. When intake decreases (illness, diet change, hospital admission on clear fluids), the INR rises.
The Caribbean diet is rich in Vitamin K-containing foods. The clinical challenge is not to eliminate these foods -- they are nutritious and important -- but to maintain consistent intake from week to week.
High Vitamin K Caribbean foods:
| Food | Vitamin K content | Practical note |
|---|---|---|
| Callaloo (Amaranthus or Taro leaves) | Very high (300-600 mcg per serving) | Eaten multiple times weekly in many households |
| Dasheen leaves (Taro leaves) | Very high | Used in callaloo preparation |
| Pak choi / bok choy | High (150-250 mcg per serving) | Common in Chinese-Trinidadian and other communities |
| Spinach | High (145 mcg per 100g) | Widely available |
| Broccoli | Moderate-High (100 mcg per 100g) | |
| Cabbage (cooked) | Moderate | Less concentrated than leafy greens |
| Green onions (scallion) | Moderate | Used in large quantities in Caribbean cooking |
| Coconut oil | Very low | |
| Avocado | Low-moderate | Small amount of Vitamin K |
The principle of consistent intake: The goal is not to restrict Vitamin K but to maintain consistent intake. A patient who eats callaloo four times a week every week will have a predictable INR. A patient who eats it rarely and then has a large amount at a family event will have a transient INR drop.
Practical counsel: Ask about Vitamin K-containing food frequency at every INR review. Any significant change in eating pattern -- illness reducing appetite, dietary change, travel -- should prompt an earlier INR check.
Section 5: Drug Interactions -- Every Clinically Significant Interaction in One Table
Warfarin interactions are among the most extensive of any drug. The following table covers the interactions encountered most commonly in Caribbean practice.
| Interacting drug | Direction of INR change | Mechanism | Action |
|---|---|---|---|
| Antibiotics | |||
| Metronidazole | INR rises significantly | CYP2C9 inhibition (Report 12) | Check INR 2-3 days after starting; expect dose reduction |
| Fluconazole | INR rises significantly | CYP2C9 + CYP3A4 inhibition | Check INR 2-3 days after starting; expect dose reduction |
| Clarithromycin / erythromycin | INR rises | CYP3A4 inhibition | Monitor INR closely |
| Ciprofloxacin | INR rises | Reduced gut Vitamin K production + CYP1A2 inhibition | Monitor; unpredictable magnitude |
| Azithromycin | INR rises modestly | Mechanism uncertain | Monitor with prolonged courses |
| Rifampicin | INR falls significantly | Potent CYP enzyme induction | Major dose increase required; specialist review |
| Trimethoprim-sulfamethoxazole | INR rises significantly | CYP2C9 inhibition | High-risk combination; close INR monitoring |
| Cardiovascular | |||
| Amiodarone | INR rises substantially | CYP2C9 + CYP3A4 inhibition | Prolonged effect; reduce warfarin 30-50%; frequent monitoring |
| Aspirin | No INR change; GI bleed risk | Antiplatelet + GI mucosal damage | Additive bleeding risk; avoid combination unless clearly indicated |
| Statins (simvastatin, atorvastatin, lovastatin) | INR rises modestly | CYP2C9 competition | Monitor on initiation; usually stable once established |
| Diltiazem | INR rises modestly | CYP3A4 inhibition | Monitor; usually small effect |
| Analgesics | |||
| NSAIDs (ibuprofen, diclofenac, naproxen) | No INR change; GI bleed risk | Antiplatelet + GI mucosal damage | High-risk combination; avoid if possible; substitute paracetamol |
| Paracetamol (high-dose chronic) | INR rises modestly | Mechanism uncertain | Monitor if above 2 g/day for more than 3 days |
| GI drugs | |||
| Omeprazole | INR rises modestly | CYP2C19 inhibition of warfarin minor pathway | Usually small effect; esomeprazole higher effect |
| Psychotropics | |||
| Fluoxetine / paroxetine (SSRIs) | INR rises | CYP2C9 inhibition | Monitor on initiation (Report 11) |
| Thyroid | |||
| Levothyroxine | INR rises | Increased clotting factor catabolism in hyperthyroid state | Monitor when thyroid dose changes |
| Inducers | |||
| Carbamazepine | INR falls significantly | Potent CYP3A4 + 2C9 induction (Report 12) | Major dose increase required |
| Phenytoin | INR falls then rises (complex) | Initial induction then inhibition | Unpredictable; frequent monitoring; specialist review |
| St. John's Wort | INR falls | CYP3A4 induction | Avoid combination; ask about herbal use (Report 3) |
Section 6: Herbal Interactions
Caribbean patients on warfarin frequently use herbal products (Report 3). The most relevant:
| Herb | Effect on INR | Mechanism |
|---|---|---|
| Ginger (high dose supplements) | INR rises | Antiplatelet activity; additive bleeding risk |
| Garlic (supplement doses) | INR rises | Antiplatelet activity |
| Ginkgo biloba | INR rises | Antiplatelet activity |
| St. John's Wort | INR falls | CYP3A4 induction (Report 12) |
| Cranberry juice (large amounts) | INR rises | CYP2C9 inhibition |
| Guinea hen weed | Possible INR rise | Coumarin derivatives; antiplatelet activity (Report 3) |
| Soursop leaf tea | No direct INR effect documented; theoretical | Additive hypotensive risk; monitor for bleeding symptoms |
The three questions from Report 3 apply at every anticoagulation review. Undisclosed herbal use is a common contributor to unexplained INR instability.
Section 7: Managing INR Out of Range
7.1 INR above range
| INR | Situation | Action |
|---|---|---|
| 3.0 -- 4.5 | No bleeding | Reduce warfarin dose 10-15%; recheck INR in 1 week |
| 4.5 -- 8.0 | No bleeding | Hold 1-2 doses; reduce maintenance dose; recheck in 2-3 days |
| 4.5 -- 8.0 | Minor bleeding | Hold warfarin; consider low-dose oral phytomenadione (Vitamin K1) 1-2 mg; recheck in 24 hours |
| Above 8.0 | No or minor bleeding | Hold warfarin; oral phytomenadione 2.5-5 mg; urgent recheck in 12-24 hours |
| Any INR | Major bleeding | Emergency: hold warfarin; IV phytomenadione 5-10 mg over 20 minutes; prothrombin complex concentrate (PCC) or fresh frozen plasma if PCC unavailable; call specialist immediately |
Caribbean practice note: Vitamin K (phytomenadione) availability varies across the Caribbean. Oral Vitamin K1 tablets are not reliably stocked in all territories. Clinicians should know what is available locally. Where oral Vitamin K is unavailable, dietary Vitamin K-rich foods (a serving of callaloo or spinach) can provide a modest corrective effect for mildly supratherapeutic INRs in stable patients, but this is not a substitute for phytomenadione in significant over-anticoagulation.
7.2 INR below range
| INR | Situation | Action |
|---|---|---|
| 1.5 -- 2.0 | No thrombotic symptoms | Increase warfarin dose 10-15%; recheck in 1 week; review for dietary change, missed doses, or new inducing drug |
| Below 1.5 | No thrombotic symptoms | Increase dose more substantially; recheck in 4-5 days; consider bridging with LMWH in high-risk indications (mechanical valves, recent PE) |
| Any INR | Thrombotic symptoms | Urgent clinical assessment; LMWH bridging; specialist review |
Section 8: Direct Oral Anticoagulants -- The Alternative and Its Limitations
Direct oral anticoagulants (DOACs) -- apixaban, rivaroxaban, dabigatran, edoxaban -- have largely replaced warfarin in high-income settings for atrial fibrillation and VTE. They have fixed dosing, no dietary interactions, fewer drug interactions, and do not require routine INR monitoring.
8.1 Advantages over warfarin
- No Vitamin K dietary interactions
- Fewer drug interactions (though CYP3A4 and P-glycoprotein interactions exist)
- Fixed dosing without routine monitoring
- At least equivalent efficacy to warfarin for AF stroke prevention
- Lower risk of intracranial haemorrhage in most trials
8.2 DOAC limitations in Caribbean practice
| Limitation | Detail |
|---|---|
| Cost | DOACs are substantially more expensive than warfarin and are not included in most Caribbean public sector formularies |
| Reversal availability | Specific DOAC reversal agents (idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors) are expensive and rarely available in Caribbean facilities |
| Renal clearance | Dabigatran requires CrCl above 30; rivaroxaban and apixaban require dose reduction or avoidance in CKD (Report 2). Warfarin, paradoxically, does not require renal dose adjustment |
| Not suitable for mechanical heart valves | DOACs are contraindicated with mechanical prosthetic heart valves -- warfarin remains the only oral anticoagulant option |
| Monitoring | The absence of routine monitoring is an advantage in stable patients but a disadvantage in patients where adherence is uncertain -- there is no INR to detect non-adherence |
| Drug interactions | Apixaban and rivaroxaban are CYP3A4 and P-glycoprotein substrates -- clarithromycin, itraconazole, and rifampicin interactions are significant |
8.3 Where DOACs are the better choice (when accessible and affordable)
- Atrial fibrillation in patients with poor INR stability despite adherent behaviour
- VTE in patients with frequent antibiotic or NSAID use (multiple warfarin interaction episodes)
- Patients where INR monitoring access is severely limited
- Atrial fibrillation with concurrent CYP2C9 inhibitor that cannot be stopped
8.4 Where warfarin remains the only option
- Mechanical heart valves (all types)
- Patients where DOAC cost is prohibitive
- Patients with severe renal impairment where available DOACs are contraindicated
Section 9: The Anticoagulation Monitoring Checklist
Print and use at every warfarin clinic visit.
| Check | Frequency | Action when abnormal |
|---|---|---|
| INR | Every 4-6 weeks when stable (more frequently during initiation, dose change, illness, or new drug) | Adjust dose per Table in Section 7 |
| Current medication list | Every visit | Check for new interactions (Section 5) |
| Herbal and OTC product use | Every visit | Apply three questions (Report 3); adjust monitoring if new herbal identified |
| Dietary Vitamin K pattern | Every visit | Counsel on consistency; arrange earlier INR if dietary change noted |
| Signs of bleeding | Every visit | Bruising, haematuria, prolonged bleeding from cuts, blood in stool |
| Signs of thrombosis | Every visit | Leg swelling, chest pain, breathlessness, new neurological symptoms |
| Renal function | Annually or after acute illness | CrCl decline does not require warfarin dose adjustment but affects DOAC eligibility |
| Compliance / adherence | Every visit | Missed doses are a common cause of sub-therapeutic INR |
| Indication review | Annually | Is the original indication for anticoagulation still present? Has the benefit-risk ratio changed? |
Section 10: About ElesRx
ElesRx flags warfarin drug interactions automatically across all interaction mechanisms -- CYP2C9 and CYP3A4 inhibition and induction, pharmacodynamic interactions (NSAIDs, antiplatelet drugs, SSRIs), and herbal interactions. When a new drug is added to a patient's list that includes warfarin, the system generates an alert specifying the direction and expected magnitude of the INR change and the recommended monitoring action.
The tool is available at elesrx.com. ElesRx is a product of PIPPS Smart Apps, a division of J.C. Epiphany Limited (Jamaica, est. 1998).
Section 11: Methodology and References
11.1 Data sources
Anticoagulation data is drawn from the ElesRx clinical database, DailyMed, the European Medicines Agency, Health Canada, and published clinical guidelines. Vitamin K food content data references the USDA FoodData Central database. Drug interaction data cross-references Report 12 (CYP450 Report).
11.2 Limitations
Warfarin management in patients with mechanical heart valves, antiphospholipid syndrome, or during pregnancy requires specialist-level anticoagulation expertise. This report covers primary care and general medicine anticoagulation management.
DOAC dosing in specific clinical situations (renal impairment, obesity, drug interactions) requires current prescribing information -- the field is evolving and this report's DOAC section reflects evidence current to mid-2026.
11.3 Author and conflict of interest disclosure
This report was authored by Juliet Duncan, BPharm, founder of J.C. Epiphany Limited and developer of ElesRx. The author has a commercial interest in ElesRx. This report is published without an access gate as a contribution to Caribbean clinical education. No external funding was received.
11.4 Citation
Duncan J. The Anticoagulation Report: Managing Warfarin and Anticoagulation in Caribbean Practice. ElesRx Clinical Reports, Report 15. Published 2027 at elesrx.com/reports/anticoagulation-report/. J.C. Epiphany Limited, Jamaica.
References
-
Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095-1106. doi:10.1001/archinte.165.10.1095
-
Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing (COAG trial). N Engl J Med. 2013;369(24):2283-2293. doi:10.1056/NEJMoa1310669
-
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962. doi:10.1016/S0140-6736(13)62343-0
-
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612
-
Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenomics Implementation Consortium (CPIC) guideline for pharmacogenomics-guided warfarin dosing. Clin Pharmacol Ther. 2017;102(3):397-404. doi:10.1002/cpt.668